⌘K
Loading ticker…
As of 2026-08-24, Monte Rosa Therapeutics, Inc. Common Stock (GLUE) has a 3-month relative strength percentile of 16 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 57. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.2%, relative volume 1.31×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
GLUE appears in 1 ETF as of Jun 2026: PSC at 0.04% weight, $1M notional.
Held by 57 ETFs · $210M across latest filings · largest weight 0.87% (BBC).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.04% | $1M | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GLUE Jan avg: 4.45% median: -3.40% win: 25% σ: 17.67% n: 4 2022-04-12 → 2026-07-31 | GLUE Feb avg: -7.30% median: -15.46% win: 25% σ: 18.00% n: 4 2022-04-12 → 2026-07-31 | GLUE Mar avg: 4.13% median: 2.02% win: 50% σ: 19.58% n: 4 2022-04-12 → 2026-07-31 | GLUE Apr avg: -11.68% median: -14.37% win: 40% σ: 23.29% n: 5 2022-04-12 → 2026-07-31 | GLUE May avg: -0.19% median: -14.87% win: 40% σ: 37.05% n: 5 2022-04-12 → 2026-07-31 | GLUE Jun avg: 7.84% median: 7.90% win: 60% σ: 16.06% n: 5 2022-04-12 → 2026-07-31 | GLUE Jul avg: -0.82% median: 3.21% win: 60% σ: 19.89% n: 5 2022-04-12 → 2026-07-31 | GLUE Aug avg: 0.95% median: -7.85% win: 25% σ: 24.41% n: 4 2022-04-12 → 2026-07-31 (current) | GLUE Sep avg: 6.26% median: -5.47% win: 50% σ: 33.40% n: 4 2022-04-12 → 2026-07-31 | GLUE Oct avg: 29.34% median: 36.49% win: 75% σ: 46.87% n: 4 2022-04-12 → 2026-07-31 | GLUE Nov avg: 7.77% median: 7.03% win: 50% σ: 18.66% n: 4 2022-04-12 → 2026-07-31 | GLUE Dec avg: 8.99% median: -6.64% win: 25% σ: 50.49% n: 4 2022-04-12 → 2026-07-31 |